WHAT IS CLAIMED IS:

1. A mixed carrier, multivalent pneumococcal conjugate composition or a vaccine comprising said mixed carrier, multivalent pneumococcal conjugate composition and a pharmaceutically acceptable excipient for use in the prophylaxis against *Streptococcus pneumoniae* infection or disease in a human subject,

wherein the mixed carrier, multivalent pneumococcal conjugate composition comprises 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F,

wherein the protein carrier is CRM_{197} or tetanus toxoid, and

wherein four of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM_{197}, wherein the four capsular polysaccharides that are conjugated to tetanus toxoid are serotypes 15B, 22F and the other two serotypes selected from the group consisting of serotypes 1, 3, and 5.

2. The mixed carrier, multivalent pneumococcal conjugate composition or the vaccine for use of claim 1, wherein the capsular polysaccharides from serotypes 1, 5, 15B and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM_{197}.

3. The mixed carrier, multivalent pneumococcal conjugate composition or the vaccine for use of claim 1, wherein:

a) the capsular polysaccharides from serotypes 1, 3, 15B and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM_{197}; or

b) the capsular polysaccharides from serotypes 3, 5, 15B and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM_{197}.

4. The mixed carrier, multivalent pneumococcal conjugate composition or the vaccine for use of any one of claims 1-3, further comprising an adjuvant, optionally wherein the adjuvant

is an aluminum-based adjuvant, such as aluminum phosphate, aluminum sulfate, or aluminum hydroxide, preferably wherein the adjuvant is aluminum phosphate.

5. The mixed carrier, multivalent pneumococcal conjugate composition or the vaccine for use of any one of claims 1-4, wherein:

the capsular polysaccharide from serotype 9N is conjugated to CRM_{197} in a state where the capsular polysaccharide from serotype 9N is activated to have a degree of oxidation of 2-19 or 5-10 and a molecular weight of 200-700 kDa;

the conjugate formed between the capsular polysaccharide from serotype 9N and CRM_{197} has a molecular weight of 500-4,000 kDa;

a ratio of the capsular polysaccharide from serotype 9N to CRM_{197} in the conjugate formed between the capsular polysaccharide from serotype 9N and CRM_{197} is 0.5-2.5 (w/w); and/or

15-60 % of the conjugate formed between the capsular polysaccharide from serotype 9N and CRM_{197} has a K_d of 0.3 or below in a CL-4B column.

6. The mixed carrier, multivalent pneumococcal conjugate composition or the vaccine for use of any one of claims 1-5, wherein:

a) the subject is a human who is at least 50 years old and the disease is pneumonia or invasive pneumococcal disease (IPD); or

b) the subject is a human who is at least 6 weeks old, such as 6 weeks to 5 years of age, 2 to 15 months of age, or 6 to 17 years of age, and the disease is pneumonia, invasive pneumococcal disease (IPD), or acute otitis media (AOM).

7. The mixed carrier, multivalent pneumococcal conjugate composition or the vaccine for use of any one of claims 1-6, wherein:

a) the mixed carrier, multivalent pneumococcal conjugate composition or the vaccine is administered by intramuscular injection; and/or

b) the mixed carrier, multivalent pneumococcal conjugate composition or the vaccine is administered as part of an immunization series.

8. The vaccine for use of any one of claims 1-7, wherein the 21 different pneumococcal capsular polysaccharide-protein conjugates comprise the capsular polysaccharides from serotypes 1, 5, 15B and 22F, each of which is conjugated to the tetanus toxoid, and the capsular

polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F, each of which is conjugated to CRM_{197}, wherein the vaccine is formulated as a single 0.5 ml dose comprising 1 μg to 5 μg of each capsular polysaccharide.

9. The vaccine for use of claim 8, wherein the vaccine comprises:

2 μg to 25 μg of tetanus toxoid;

40 μg to 75 μg of CRM_{197};

0.125 to 0.250 mg of elemental aluminum adjuvant, wherein the elemental aluminum adjuvant preferably comprises aluminum phosphate;

sodium chloride;

a succinate buffer; and

optionally polysorbate 80.

10. Use of a mixed carrier, multivalent pneumococcal conjugate composition or a vaccine comprising said mixed carrier, multivalent pneumococcal conjugate composition and a pharmaceutically acceptable excipient for the manufacture of a medicament for prophylaxis against *Streptococcus pneumoniae* infection or disease in a subject, preferably a human,

wherein the mixed carrier, multivalent pneumococcal conjugate composition comprises 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of *Streptococcus pneumoniae*, wherein the *Streptococcus pneumoniae* serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F,

wherein the protein carrier is CRM_{197} or tetanus toxoid, and

wherein four of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM_{197}, wherein the four capsular polysaccharides that are conjugated to tetanus toxoid are serotypes 15B, 22F and the other two serotypes selected from the group consisting of serotypes 1, 3, and 5.

11. The use of claim 10, wherein the capsular polysaccharides from serotypes 1, 5, 15B and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM_{197}.

12. The use of claim 10, wherein:

a) the capsular polysaccharides from serotypes 1, 3, 15B and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM_{197}; or

b) the capsular polysaccharides from serotypes 3, 5, 15B and 22F are conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 1, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 18C, 19A, 19F, 23F, and 33F are conjugated to CRM_{197}.

13. The use of any one of claims 10-12, wherein the mixed carrier, multivalent pneumococcal conjugate composition or the vaccine further comprises an adjuvant, optionally wherein the adjuvant is an aluminum-based adjuvant, such as aluminum phosphate, aluminum sulfate, or aluminum hydroxide, preferably wherein the adjuvant is aluminum phosphate.

14. The use of any one of claims 10-13, wherein:

the capsular polysaccharide from serotype 9N is conjugated to CRM_{197} in a state where the capsular polysaccharide from serotype 9N is activated to have a degree of oxidation of 2-19 or 5-10 and a molecular weight of 200-700 kDa;

the conjugate formed between the capsular polysaccharide from serotype 9N and CRM_{197} has a molecular weight of 500-4,000 kDa;

a ratio of the capsular polysaccharide from serotype 9N to CRM_{197} in the conjugate formed between the capsular polysaccharide from serotype 9N and CRM_{197} is 0.5-2.5 (w/w); and/or

15-60 % of the conjugate formed between the capsular polysaccharide from serotype 9N and CRM_{197} has a K_d of 0.3 or below in a CL-4B column.

15. The use of any one of claims 10-14, wherein:

a) the subject is a human who is at least 50 years old and the disease is pneumonia or invasive pneumococcal disease (IPD); or

b) the subject is a human who is at least 6 weeks old, such as 6 weeks to 5 years of age, 2 to 15 months of age, or 6 to 17 years of age, and the disease is pneumonia, invasive pneumococcal disease (IPD), or acute otitis media (AOM).

16. The use of any one of claims 10-15, wherein:

a) the mixed carrier, multivalent pneumococcal conjugate composition or the vaccine is formulated for administration by intramuscular injection; and/or

b) the mixed carrier, multivalent pneumococcal conjugate composition or the vaccine is formulated for administration as part of an immunization series.

17. The use of any one of claims 10-16, wherein the 21 different pneumococcal capsular polysaccharide-protein conjugates comprise the capsular polysaccharides from serotypes 1, 5, 15B and 22F, each of which is conjugated to the tetanus toxoid, and the capsular polysaccharides from serotypes 3, 4, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 23F, and 33F, each of which is conjugated to CRM_{197}, and wherein the vaccine is formulated as a single 0.5 ml dose comprising 1 μg to 5 μg of each capsular polysaccharide.

18. The use of claim 17, wherein the vaccine comprises:

2 μg to 25 μg of tetanus toxoid;

40 μg to 75 μg of CRM_{197};

0.125 to 0.250 mg of elemental aluminum adjuvant, wherein the elemental aluminum adjuvant preferably comprises aluminum phosphate;

sodium chloride;

a succinate buffer; and

optionally polysorbate 80.

19. The use of claim 8 or 17, wherein the vaccine comprises 2 μg to 2.5 μg or 4 μg to 5 μg of each capsular polysaccharide